- Board of Directors
Dr. David M. Goldenberg founded Immunomedics in July 1982, and has served continuously since that time as the Chairman of our Board of Directors. He also currently serves as our Chief Scientific Officer and Chief Patent Officer, having been our Chief Medical Officer from July 2007 to December 2014, Chief Strategic Officer from July 2003 to July 2007. Dr. Goldenberg previously served as our Chief Executive Officer from July 1982 through July 1992, from February 1994 through May 1998 and from July 1999 through March 2001. He also serves as Chairman of the Board of Directors of IBC Pharmaceuticals, Inc., a subsidiary of Immunomedics.
Dr. Goldenberg is a graduate of the University of Chicago College and Division of Biological Sciences (B.S.), the University of Erlangen-Nuremberg (Germany) Faculty of Natural Sciences (Sc.D.), and the University of Heidelberg (Germany) School of Medicine (M.D.). He has written or co-authored approximately 1,700 journal articles, book chapters and abstracts on cancer research, detection and treatment, and has researched and written extensively in the area of radioimmunodetection and radioimmunotherapy using radiolabeled antibodies.
Dr. Goldenberg was President and a Trustee of the Center for Molecular Medicine and Immunology (“CMMI”), an independent non-profit research center, and its clinical unit, the Garden State Cancer Center. In 1985 and again in 1992, Dr. Goldenberg received an “Outstanding Investigator Grant” award from the National Cancer Institute for his work in radioimmunodetection, and in 1986 he received the New Jersey Pride Award in Science and Technology.
Dr. Goldenberg was honored as the ninth Herz Lecturer of the Tel Aviv University Faculty of Life Sciences. In addition, he received the 1991 Mayneord 3M Award and Lectureship of the British Institute of Radiology and in 2002, the Elis Bervin Lectureship and Medal from the Swedish Medical Society and the Swedish Oncology Society for his contributions to the development of radiolabeled monoclonal antibodies used in the imaging and treatment of cancer. The International Society for Oncodevelopmental Biology and Medicine named Dr. Goldenberg the co-recipient of the 1994 Abbott Award. In 2005, he received the Paul Aebersold Award from the Society of Nuclear Medicine and was named the Inventor of the Year by the Research and Development Council of New Jersey. Maryann Liebert Inc., publisher of Genetic Engineering News, nominated Dr. Goldenberg in 2006 for the Forbes Enterprise Award for outstanding achievements in the scientific community.
Arthur S. Kirsch is a Senior Advisor with GCA Savvian, LLC, an investment bank. Mr. Kirsch has over 30 years of experience working in the equity capital markets and has extensive knowledge of the healthcare and life sciences field. Prior to GCA Savvian, he was a founding member and Managing Director of Vector Securities, LLC, an investment and merchant banking firm specializing in bioscience, which later became a unit of Prudential Securities, Inc. Prior to Vector, Mr. Kirsch was President and Chief Executive Officer of NatWest Securities U.S. From 1979 to 1990, he served as Executive Vice President of the Global Equity Division of Drexel Burnham Lambert. Since June 1, 2015, Mr. Kirsch has been Chairman of the Board of Pozen Inc., a progressive pharmaceutical company committed to transforming medicine that transforms lives, serving as a Director since 2004; he also has been Chairman of the Audit Committee and Head of the Strategic Transaction Committee of Pozen. Mr. Kirsch also serves on the Board of Directors of PhysioSonics, Inc., a privately-held company developing noninvasive neurological products.
Brian A. Markison is a Healthcare Industry Executive at Avista Capital Partners, a leading private equity firm. Previously, Mr. Markison served as the President, Chief Executive Officer and a member of the Board of Directors of Fougera Pharmaceuticals, a company created from the acquisition of Nycomed A/S by Takeda Pharmaceuticals. Effective July 23, 2012, Fougera Pharmaceuticals was acquired by Novartis AG. From 2004 to 2011, he was President and Chief Executive Officer of King Pharmaceuticals, Inc. and elected Chairman of the Board of Directors in 2007. Effective February 28, 2011, King Pharmaceuticals, Inc. was acquired by Pfizer Inc. Prior to joining King Pharmaceuticals, Mr. Markison was the President of Oncology, Virology and Oncology Therapeutics Network Business at Bristol-Meyers Squibb. During his 22-year career at Bristol-Meyers Squibb, he distinguished himself in the areas of sales, marketing, international and domestic general management positions. Mr. Markison also serves as the Chairman of the Board of Directors for Rosetta Genomics, Ltd., a leading developer of microRNA-based molecular diagnostics, and a Director for PharmAthene, Inc., a biodefense company developing medical countermeasures against biological and chemical threats.
Mary E. Paetzold is the Chief Financial Officer of SMG Indium Resources Ltd., a company whose primary business purpose is to purchase and stockpile indium, a specialty metal that is being increasingly used as a raw material in a wide variety of consumer electronics manufacturing applications. A Certified Public Accountant with over 35 years of experience with public and private companies, Ms. Paetzold was an Adjunct Professor at the Cameron School of Business, University of North Carolina – Wilmington, from 2008 to 2009. From 1994 to 2000 she was Vice President, Chief Financial Officer, Secretary, Treasurer and a member of the Board of Directors from 1996 to 1997 of Ecogen, Inc. Prior thereto, Ms. Paetzold was an audit partner and SEC reviewing partner for KPMG LLP, in Short Hills, New Jersey, where she worked for 21 years. She also served as chairperson of the Advisory Council of the School of Business at Montclair State University, where she earned an undergraduate degree in mathematics. Ms. Paetzold previously served from 2003 to 2011 as a Director of Orthovita, a specialty spine and orthopedic company with orthobiologic and biosurgery products.
Don C. Stark is the Chief Executive Officer and President of Whistler Associates, Inc., a marketing and strategic planning consulting firm for companies focused on oncology. Prior to founding Whistler Associates, Inc., in 1996, Mr. Stark held various market research, marketing and business development positions at Bristol-Myers Squibb Oncology Division, Immunex, and Repligen, all in the fields of oncology and immunology. Mr. Stark has concurrently served as partner and member of the Board of Directors of Strategic Answers Inc., a forecasting and information service provider to the pharmaceutical industry.
Ms. Cynthia L. Sullivan has been employed by Immunomedics since October 1985, and has served as our President and Chief Executive Officer since March 2001. She previously served as the Company’s President from December 2000 to March 2001 and as Executive Vice President and Chief Operating Officer from June 1999 to December 2000. Prior to joining Immunomedics, Ms. Sullivan was employed by Ortho Diagnostic Systems, Inc., a subsidiary of Johnson & Johnson.
Ms. Sullivan’s educational background includes: a B.S. from Merrimack College, North Andover, Massachusetts, followed by a year of clinical internship with the school of Medical Technology at Muhlenberg Hospital, Plainfield, New Jersey, resulting in a M.T. (ASCP) certification in 1979. Ms. Sullivan completed a M.S. degree in 1986 from Fairleigh Dickinson University, where she also received her M.B.A. in December 1991.
Ms. Sullivan also serves as President of our majority owned subsidiary, IBC Pharmaceuticals, Inc. From September 2002 to July 2007, Ms. Sullivan served as a member of the Board of Directors of Digene Corp., a company that develops, manufactures and markets proprietary DNA and RNA testing systems for the screening, monitoring and diagnosis of human diseases. Effective July 30, 2007 Digene Corp was merged with Qiagen N.V. As of May 2009, Ms. Sullivan also serves as a member of Board of Trustees for the HealthCare Institute of New Jersey, a trade association for the research-based pharmaceutical and medical technology industry in New Jersey.